Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria.
Djimdé AA, Tekete M, Abdulla S, Lyimo J, Bassat Q, Mandomando I, Lefèvre G, Borrmann S; B2303 Study Group. Djimdé AA, et al. Among authors: lyimo j. Antimicrob Agents Chemother. 2011 Sep;55(9):3994-9. doi: 10.1128/AAC.01115-10. Epub 2011 Jun 13. Antimicrob Agents Chemother. 2011. PMID: 21670177 Free PMC article. Clinical Trial.
Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial.
Abdulla S, Sagara I, Borrmann S, D'Alessandro U, González R, Hamel M, Ogutu B, Mårtensson A, Lyimo J, Maiga H, Sasi P, Nahum A, Bassat Q, Juma E, Otieno L, Björkman A, Beck HP, Andriano K, Cousin M, Lefèvre G, Ubben D, Premji Z. Abdulla S, et al. Among authors: lyimo j. Lancet. 2008 Nov 22;372(9652):1819-27. doi: 10.1016/S0140-6736(08)61492-0. Epub 2008 Oct 14. Lancet. 2008. PMID: 18926569 Free article. Clinical Trial.
Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges.
Bassat Q, González R, Machevo S, Nahum A, Lyimo J, Maiga H, Mårtensson A, Bashraheil M, Ouma P, Ubben D, Walter V, Nwaiwu O, Kipkeu C, Lefèvre G, Ogutu B, Menéndez C. Bassat Q, et al. Among authors: lyimo j. Malar J. 2011 Dec 16;10:369. doi: 10.1186/1475-2875-10-369. Malar J. 2011. PMID: 22176931 Free PMC article. Clinical Trial.
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, Owusu R, Shomari M, Leach A, Jongert E, Salim N, Fernandes JF, Dosoo D, Chikawe M, Issifou S, Osei-Kwakye K, Lievens M, Paricek M, Möller T, Apanga S, Mwangoka G, Dubois MC, Madi T, Kwara E, Minja R, Hounkpatin AB, Boahen O, Kayan K, Adjei G, Chandramohan D, Carter T, Vansadia P, Sillman M, Savarese B, Loucq C, Lapierre D, Greenwood B, Cohen J, Kremsner P, Owusu-Agyei S, Tanner M, Lell B. Asante KP, et al. Among authors: lyimo j. Lancet Infect Dis. 2011 Oct;11(10):741-9. doi: 10.1016/S1473-3099(11)70100-1. Epub 2011 Jul 22. Lancet Infect Dis. 2011. PMID: 21782519 Free article. Clinical Trial.
Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization.
Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R, Shomari M, Leach A, Fernandes J, Dosoo D, Chikawe M, Issifou S, Osei-Kwakye K, Lievens M, Paricek M, Apanga S, Mwangoka G, Okissi B, Kwara E, Minja R, Lange J, Boahen O, Kayan K, Adjei G, Chandramohan D, Jongert E, Demoitié MA, Dubois MC, Carter T, Vansadia P, Villafana T, Sillman M, Savarese B, Lapierre D, Ballou WR, Greenwood B, Tanner M, Cohen J, Kremsner PG, Lell B, Owusu-Agyei S, Abdulla S. Agnandji ST, et al. Among authors: lyimo j. J Infect Dis. 2010 Oct 1;202(7):1076-87. doi: 10.1086/656190. J Infect Dis. 2010. PMID: 20735271 Clinical Trial.
Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania.
Fimbo A, Mwalwisi YH, Mwamwitwa K, Matiko D, Mfinanga E, Lyimo J, Sabasaba A, Missago S, Bukundi E, Gotora G, Respick D, Nkayamba A, Masunga E, Mnkugwe RH, Kunambi PP, Munishi C, Musanhu CC, Minzi OMS, Mlugu EM. Fimbo A, et al. Among authors: lyimo j. Sci Rep. 2024 Jan 5;14(1):615. doi: 10.1038/s41598-023-51144-7. Sci Rep. 2024. PMID: 38182720 Free PMC article.
25 results